Evidence for immunosurveillance in intestinal premalignant lesions

Scandinavian Journal of Immunology

Volumn 71, Issue 5, 2010, Pages 362-368

  Karlsson, M ^a   Lindberg, K ^a   Karlen P ^a   Ost A ^b   Thorn M ^a   Winqvist, O ^b,c   Eberhardson, M ^a  

^a STOCKHOLM SÖDER HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; COLON RESECTION; CONTROLLED STUDY; DISEASE SEVERITY; DYSPLASIA; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; INTESTINE MUCOSA; LYMPHOCYTE PROLIFERATION; MALE; PRECANCER; PRIORITY JOURNAL; SENTINEL LYMPH NODE; ULCERATIVE COLITIS;

CARCINOMA; CD4-CD8 RATIO; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; COLITIS, ULCERATIVE; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOLOGIC SURVEILLANCE; INTESTINAL MUCOSA; LYMPH NODES; MALE; MESENTERY; MIDDLE AGED; PRECANCEROUS CONDITIONS; SENTINEL LYMPH NODE BIOPSY; T-LYMPHOCYTE SUBSETS;

EID: 77951086632     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2010.02377.x     Document Type: Article

References (31)

1. Lapidus A, Bernell O, Hellers G, Persson PG, Lofberg R. Incidence of Crohn's disease in Stockholm County 1955-1989. Gut 1997 41 : 480 486.
2. Tysk C, Jarnerot G. Ulcerative proctocolitis in Orebro, Sweden. A retrospective epidemiologic study, 1963-1987. Scand J Gastroenterol 1992 27 : 945 950.
3. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003 3 : 521 533.
4. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001 48 : 526 535.
5. Soderlund S, Brandt L, Lapidus A et al. Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease. Gastroenterology 2009 136 : 1561 1567 quiz 818-9.
6. Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol 2004 287 : G7 17.
7. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002 3 : 991 998.
8. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004 22 : 329 360.
9. Dougan M, Dranoff G. The immune response to tumors. Curr Protoc Immunol 2009 20 : Unit 20 11 : 1 4.
10. Koebel CM, Vermi W, Swann JB et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007 450 : 903 907.
11. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev 2006 6 : 715 727.
12. Eberhardson M, Lindberg K, Karlsson M, Karlen P, Winqvist O, Thorn M. The sentinel node technique is useful for studies of intestinal immunology in inflammatory bowel disease patients. Eur J Gastroenterol Hepatol 2008 20 : 985 988.
13. Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 2006 90 : 1 50.
14. Marits P, Karlsson M, Dahl K et al. Sentinel node lymphocytes: tumour reactive lymphocytes identified intraoperatively for the use in immunotherapy of colon cancer. Br J Cancer 2006 94 : 1478 1484.
15. Earlich P. Ueber den jetzigen Stand der Karzinomaforschung. Ned Tijdschr Geneeskd 1909 5 : 273 290.
16. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004 21 : 137 148.
17. Woolrich AJ, DaSilva MD, Korelitz BI. Surveillance in the routine management of ulcerative colitis: the predictive value of low-grade dysplasia. Gastroenterology 1992 103 : 431 438.
18. Ward PL, Koeppen HK, Hurteau T, Rowley DA, Schreiber H. Major histocompatibility complex class I and unique antigen expression by murine tumors that escaped from CD8+ T-cell-dependent surveillance. Cancer Res 1990 50 : 3851 3858.
19. Yu P, Fu YX. Tumor-infiltrating T lymphocytes: friends or foes? Lab Invest 2006 86 : 231 245.
20. Golumbek PT, Lazenby AJ, Levitsky HI et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991 254 : 713 716.
21. Lin KY, Guarnieri FG, Staveley-O'Carroll KF et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996 56 : 21 6.
22. Dranoff G, Jaffee E, Lazenby A et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 1993 90 : 3539 3543.
23. Zitvogel L, Mayordomo JI, Tjandrawan T et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1996 183 : 87 97.
24. Hu HM, Winter H, Urba WJ, Fox BA. Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy. J Immunol 2000 165 : 4246 4253.
25. Marits P, Karlsson M, Sherif A, Garske U, Thorn M, Winqvist O. Detection of immune responses against urinary bladder cancer in sentinel lymph nodes. Eur Urol 2006 49 : 59 70.
26. Sherif A, Hasan MN, Marits P, Karlsson M, Winqvist O, Thorn M. Feasibility of T-Cell-based adoptive immunotherapy in the first 12 patients with advanced urothelial urinary bladder cancer. Preliminary data on a new immunologic treatment based on the sentinel node concept. Eur Urol 2009 [Epub ahead of print].
27. Kohrt HE, Nouri N, Nowels K, Johnson D, Holmes S, Lee PP. Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer. PLoS Med 2005 2 : e284.
28. Yu P, Spiotto MT, Lee Y, Schreiber H, Fu YX. Complementary role of CD4+ T cells and secondary lymphoid tissues for cross-presentation of tumor antigen to CD8+ T cells. J Exp Med 2003 197 : 985 995.
29. Spiotto MT, Yu P, Rowley DA et al. Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity 2002 17 : 737 747.
30. Toes RE, Blom RJ, van der Voort E, Offringa R, Melief CJ, Kast WM. Protective antitumor immunity induced by immunization with completely allogeneic tumor cells. Cancer Res 1996 56 : 3782 3787.
31. Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 1998 393 : 474 478.